Skip to main content

Advertisement

Table 4 Logistic regression models for pCR with p values, odds ratio, and confidence intervals

From: Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial

miRNAs Patients All BC patients HER2-positive patients TNBC patients
Model Univariate Multivariate Univariate Multivariate Univariate Multivariate
miR-20a All _ _ _ _ _ _
In PM _ _ _ _ _ _
In PMCb p = 0.020 1.39 (1.05–1.84) p = 0.019 1.41 (1.06–1.89) _ _ _ _
miR-27b All _ _ p = 0.035 1.30 (1.02–1.65) p = 0.050 1.28 (1.00–1.63) _ _
In PM _ _ _ _ _ _
In PMCb p = 0.038 1.27 (1.01–1.59) p = 0.030 1.30 (1.03–1.64) _ _ _ _
miR-99b All p = 0.103 1.14 (0.97–1.34) p = 0.039 1.19 (1.01–1.41) _ _ _ _
In PM _ _ _ _ _ _
in PMCb _ _ _ _ _ _
miR-155 All p = 0.002 1.25 (1.08–1.44) p = 0.003 1.24 (1.08–1.44) p = 0.049 1.24 (1.00–1.53) p = 0.035 1.26 (1.02–1.56) p = 0.013 1.29 (1.05–1.57) p = 0.018 1.29 (1.04–1.58)
In PM p = 0.033 1.26 (1.02–1.55) p = 0.049 1.24 (1.00–1.53) _ _ _ _
In PMCb p = 0.032 1.24 (1.02–1.51) p = 0.023 1.27 (1.03–1.55) _ _ _ _
miR-193b All p = 0.039 1.13 (1.01–1.26) p = 0.055 1.12 (1.00–1.26) p = 0.010 1.26 (1.06–1.50) p = 0.012 1.26 (1.05–1.51) _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-301 All p = 0.002 1.25 (1.08–1.44) p = 0.001 1.27 (1.10–1.46) p = 0.013 1.30 (1.06–1.60) p = 0.011 1.32 (1.07–1.64) _ _
In PM p = 0.040 1.22 (1.01–1.48) p = 0.028 1.25 (1.02–1.52) _ _ _ _
In PMCb p = 0.020 1.28 (1.04–1.57) p = 0.022 1.29 (1.04–1.6) p = 0.012 1.53 (1.10–2.12) p = 0.016 1.51 (1.08–2..12) _ _
miR-365 All _ _ _ _ _ _
In PM _ _ p = 0.052 1.35 (1.00–1.81) p = 0.038 1.39 (1.02–1.90) _ _
In PMCb _ _ _ _ _ _
miR-423-5p All p = 0.048 1.19 (1.00–1.42) p = 0.064 1.18 (0.99–1.41) _ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-511 All _ _ _ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ p = 0.239 0.90 (0.76–1.07) p = 0.043 0.78 (0.62–0.99)
miR-628-5p All _ _ _ _ p = 0.024 0.81 (0.67–0.97) p = 0.017 0.79 (0.65–0.96)
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-660 All _ _ p = 0.044 1.35 (1.01–1.80) p = 0.027 1.40 (1.04–1.89) _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
miR-891a All p = 0.063 1.07 (1.00–1.15) p = 0.036 1.08 (1.01–1.16) _ _ _ _
In PM _ _ _ _ _ _
In PMCb _ _ _ _ _ _
  1. Cells filled with “-” denote insignificant miRNA contributions to the models. MiRNAs which do not show significant contributions in any population were omitted. For each miRNA variable and each patient group, a univariate as well as a multivariate model with the covariables of age, nodal status, tumor size, and grading were calculated
  2. The odds ratio with the 95% confidence interval and the associated Wald p value for the miRNAs are presented
  3. PM non-carboplatin treatment arm, PMCb carboplatin treatment arm